Check a new therapy for osteoporosis-related hip bone loss
Part of Bones, joints & muscles, Hormones & metabolism, Injuries & trauma clinical trials.
This trial studies AGN1 LOEP, a treatment being tested to improve bone strength in people with osteoporosis-related bone loss in the hip. If you qualify, you would be followed over time with clinic visits and testing to see how the treatment affects your bone health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a postmenopausal woman and have been past your last period for at least 1 year
- Your hip bone density test shows osteoporosis (femoral neck T-score of -2.5 or lower)
- You have at least one hip with no previous surgery or hip fracture
- You can take part in all study visits and follow-up testing, and you can sign written consent
- You are generally healthy enough for the study (ASA class I or II)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at people who had a special hip treatment called AGN1 LOEP to see how they are doing over time. It helps doctors learn more about the treatment's safety and how well it works.
This trial tests AGN1 LOEP (a medicine/device placed at the hip surgery site) to help prevent another hip fracture after you’ve had a low-energy hip fracture. You must be eligible for hip repair surgery and be at higher risk for another fracture, with no key exclusions like active cancer or serious kidney disease.
This study is a follow-up for people who completed a previous precision medicine trial for osteoporosis. It will monitor your bone health to see how well the treatment is working over time.
This study tests a new version of a medicine called abaloparatide (used for bone health) to see if it works the same as the approved version (Tymlos). It is for healthy adults aged 40–65 who are willing to stay at the clinic for a few days and have blood tests.
This study looks at how the natural aging of the body might affect how well bone-strengthening medications work for osteoporosis. If you are about to start one of these medications, the study will track your bone density over time to see how your response may differ based on your 'biological age.'
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.